1,3-bis(oxiran-2-ylmethoxy)-12H-benzo[b]xanthen-12-one | 1219817-09-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1,3-bis(oxiran-2-ylmethoxy)-12H-benzo[b]xanthen-12-one
• 英文别名: 1,3-bis(oxiran-2-ylmethoxy)benzo[b]xanthen-12-one
• CAS: 1219817-09-0
• 化学式: C₂₃H₁₈O₆
• 分子量: 390.392
• InChiKey: RNIFFKWXTVVICH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  69.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-羟基-3-萘甲酸 在 caesium carbonate 、 zinc(II) chloride 、 三氯氧磷 作用下， 以 丙酮 为溶剂， 反应 5.0h， 生成 1,3-bis(oxiran-2-ylmethoxy)-12H-benzo[b]xanthen-12-one
  参考文献：
  名称：

  NOVEL ANTICANCER-AIDING COMPOUND, METHOD FOR PREPARING THE SAME, ANTICANCER-AIDING COMPOSITION CONTAINING THE SAME AND METHOD FOR REDUCING ANTICANCER DRUG RESISTANCE USING THE SAME

  摘要：

  本发明提供了一种新型黄酮衍生物化合物或其药用可接受盐。该化合物可用作化疗增敏剂，可降低抗癌药物的耐药性。

  公开号：

  US20120190724A1

文献信息

• Anticancer-aiding compound, method for preparing the same, anticancer-aiding composition containing the same and method for reducing anticancer drug resistance using the same
  申请人：Na Young Hwa

  公开号：US08846749B2

  公开（公告）日：2014-09-30

  The present invention provides a novel xanthone derivative compound or a pharmaceutically acceptable salt thereof. The compound is useful as a chemosensitizer that reduces anticancer drug resistance.

  本发明提供了一种新型黄酮衍生物化合物或其药学上可接受的盐。该化合物可用作化疗增敏剂，可减少抗癌药物的耐药性。
• New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers
  作者：Hee-Ju Cho、Mi-Ja Jung、Sangwook Woo、Jungsook Kim、Eung-Seok Lee、Youngjoo Kwon、Younghwa Na

  DOI：10.1016/j.bmc.2009.12.069

  日期：2010.2

  We synthesized 12 benzoxanthone derivatives classified as three different groups based on the tetracyclic ring shapes and evaluated their pharmacological activities to find potential anticancer agents. In the cytotoxicity test, most compounds showed effective cancer cell growth inhibition against the HT29 and DU145 cell lines. Among the compounds tested, compound 19 was the most effective in the cancer cell lines tested. Compound 9 showed dual inhibitory activities against DNA relaxation by topoisomerases I and II. The% inhibition of compound 9 on topoisomerase I was comparable to that of camptothecin. Compound 9 efficiently blocked topoisomerase II function by almost threefold than etoposide at 20 mu M. Compound 19 had selective topoisomerase II inhibitory activity at 100 mu M. The DNA cross-linking test revealed that only compounds 8 and 19, which possess epoxy groups, cross-linked DNA duplex, while 14 did not. From the combined pharmacological results, we proposed that the target through which compound 19 inhibits cancer cell growth may be the DNA duplex itself and/or DNA-topoisomerase II complex. (C) 2010 Elsevier Ltd. All rights reserved.
• US8846749B2
  申请人：——

  公开号：US8846749B2

  公开（公告）日：2014-09-30